Bibliographical noteFunding Information:
We thank Hussein Al‐Mossawi and ImCheck Therapeutics for reagents and the trial volunteers. The authors received funding from the following organizations: N.M.P. (Oxford‐UCB Postdoctoral Fellowship); A.A. (Wellcome [216417/Z/19/Z]); L.C.G. (Wellcome [109028/Z/15/Z]); M.E.B.F. (Oxford‐Celgene Doctoral Fellowship). E.B. [MRC (STOP‐HCV and MR/R014485/1), NIHR Senior Investigator, NIHR BRC]; C.S.R. (NIHR BRC); A.J.P. (NIHR Senior Investigator); P.K. (Wellcome [WT109965MA], NIHR Senior Investigator). The ChAdOx1 MenB.1 trial is funded by the MRC DPFS (MRM0076931). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.